---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000282"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:08:30.628345+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Panel grants Lunai Bioworks hearing on delisting; hearing set for March 26, 2026

## Summary
- Delisting notice received Feb 6, 2026 from Nasdaq Staff; hearing request granted Feb 17, 2026.
- Hearing before Nasdaq Hearings Panel scheduled for March 26, 2026.
- Delisting action stayed pending Panel's final written decision.
- No assurance that Panel will grant continued listing or that Company can maintain compliance.

## SEC filing metadata
- accession: 0001731122-26-000282
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000282/0001731122-26-000282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000282/e7360_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000282
- JSON: https://secwatch.observer/filing/0001731122-26-000282.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000282.txt

## Source-grounded claims
- claim_id: c0af2abb43594ab8a5b1b073180c34105f7c8b49
  claim: Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding other.
  evidence_excerpt: February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. A
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000282/0001731122-26-000282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.